习近平：中法两国要抓住机遇，拓展合作空间，巩固航空、航天、核能等传统领域合作，挖掘绿色经济、数字经济、生物医药、人工智能、新能源等领域合作潜力。中方愿进口更多法国优质产品，欢迎更多法国企业来华发展，也希望法方为中国企业提供公平环境和稳定预期。中法两国人民有着天然亲近感，要深化文化、教育、科技、地方等领域交流合作，续写人文交流精彩篇章。马克龙表示，愿同中方促进相互投资，加强经贸、可再生能源等领域合作，促进友好文化交流。法方致力于推动欧中关系健康稳定发展，认为欧中应坚持对话合作，欧中应实现战略自主。面对世界地缘形势不稳、多边秩序受到冲击，法中合作更显重要，不可或缺。会谈后，两国元首共同见证签署核能、农食、教育、生态环境等领域多项合作文件。外汇交易员 (@myfxtrader):央视：12月4日上午，国家主席习近平在北京人民大会堂同来华进行国事访问的法国总统马克龙举行会谈。 ...

12月4日上午，国家主席习近平在北京人民大会堂同来华进行国事访问的法国总统马克龙举行会谈。 习近平指出，中法都是有远见、有担当的独立自主大国，是推动世界多极化、促进人类团结合作的建设性力 量。当前，百年变局加速演进，人类又一次站在何去何从的十字路口。中法两国应当展现责任担当，高举多边 主义旗帜，坚定站在历史正确一边。中方愿同法方一道，始终从两国人民根本利益和国际社会长远利益出发， 坚持平等对话、开放合作，让中法全面战略伙伴关系在"新甲子"走得更稳更好，充分彰显其战略价值，为推动 平等有序的世界多极化、普惠包容的经济全球化作出新的贡献。 习近平强调，无论外部环境如何变化，中法两国都应当始终展现大国的战略眼光和独立自主，在彼此核心利益 和重大关切问题上相互理解和支持，维护好中法关系的政治基础。中共二十届四中全会审议通过"十五五"规划 建议，为未来5年中国发展擘画蓝图，也向世界提供了一份"机遇清单"。中法两国要抓住机遇，拓展合作空 间，巩固航空、航天、核能等传统领域合作，挖掘绿色经济、数字经济、生物医药、人工智能、新能源等领域 合作潜力。中方愿进口更多法国优质产品，欢迎更多法国企业来华发展，也希望法方为中国企业提供 ...

临近年末，港股IPO的活跃仍在继续，行业普遍预期这一活跃态势将至少延续至2026年。 Wind数据显示，今年前11个月，港股市场共有91家企业完成IPO，受益于大型IPO项目，合计募集资金 2598.89亿港元，不仅是港交所时隔四年，IPO筹资额再度突破2000亿港元大关，更是一举登顶全球交易 所募资额榜首，创下募资规模新高度。其中，宁德时代(03750)、紫金黄金国际(02259)、三一重工(06031) 和赛力斯(09927)均跻身今年全球十大IPO项目。 值得关注的是，中资券商在港股IPO承销市场的角色日益突出。今年以来，共有38家保荐机构参与香港新 股发行，其中超过半数为中资券商。中金、中信、华泰占据榜单前三，承销项目数量显著领先于传统外 资大行。 安永近期发布的《中国内地和香港IPO市场报告》指出，预计2026年港股IPO市场将保持稳健增长，结构 进一步深化。上市主体方面，除A+H模式继续受到追捧外，中概股回归与特专科技公司，尤其是人工智 能、生物医药等前沿领域企业将成为重要的上市来源。 港股IPO募资总额近2600亿港元，居全球第一 Wind数据显示，今年前11个月，香港交易所共迎来91家新上市公 ...

Wind数据显示，今年前11个月港股市场共有91家企业完成IPO。合计募集资金达到2598.89亿港元。这一数据不仅助推港交所时隔四年重回2000亿港元大 关，更使其登顶全球交易所募资额榜首。宁德时代、紫金黄金国际等大型项目跻身今年全球十大IPO之列。三一重工和赛力斯同样位列其中。 对于未来的市场走势，机构普遍持审慎乐观态度。安永发布的报告指出，预计2026年港股IPO市场将保持稳健增长。市场结构有望进一步深化。A+H模式将 继续受到追捧。人工智能、生物医药等前沿领域企业将成为重要上市来源。 多空因素将在明年交织影响市场。国际长线资金逐步回流是积极信号。内地政策支持符合条件企业赴港上市也增强了市场信心。吴鹏认为，"预计港股的强 劲表现将延续至2026年"。 中资券商重塑保荐市场格局 保荐机构的市场版图已清晰显现。头部机构的优势持续凸显。中资券商在其中占据了主导地位。Livereport数据统计显示，中金国际以34单保荐数量稳居行 业首位。中信证券（香港）位列第二，保荐项目为26单。华泰金融控股（香港）以18单排名第三。 前三大机构均为中资背景。这体现了本土券商对港股市场项目资源的深度覆盖。外资机构的活跃度相对 ...

Group 1 - The 2025 Xianshang Conference was held in Fengxian District, gathering nearly 450 entrepreneurs and representatives from various industries to celebrate achievements in the private economy [1] - Fengxian is one of the most active areas for private enterprises in Shanghai, with nearly 90% of the total number of enterprises being private, contributing over 60% of industrial output value, more than half of tax revenue, and over 60% of employment [1] - The conference highlighted both established companies and new entrants, showcasing their stories as examples of the resilience and vitality of Fengxian's private economy [1] Group 2 - Yaoshu Technology, focusing on organ-on-a-chip technology, has established its R&D center in Fengxian and has gained attention from major industry players, including multinational pharmaceutical companies and leading domestic firms [2] - The organ-on-a-chip technology simulates real organ structures and functions, providing a platform for drug development, especially in light of recent changes in regulations regarding animal testing [2] - The company was attracted to Fengxian due to its clear industrial planning and supportive policies, which align with the company's development direction [3] Group 3 - Established companies like Shanghai McLean Biochemical Technology Co., Ltd. have thrived in Fengxian, successfully localizing over 2,000 high-end reagents and significantly reducing research costs for domestic institutions [4] - The company received a low-interest loan of 10 million yuan from Fengxian during a challenging period, which helped it expand its product line and achieve sales exceeding 600 million yuan last year [4] - Shanghai Pudong Electric Wire and Cable Group is investing in a new high-end intelligent manufacturing plant in Fengxian, reflecting confidence in the region's industrial environment [4] Group 4 - The company aims to implement digital production management systems and AI detection to enhance its manufacturing capabilities, addressing traditional industry pain points [5] - The "Shanghang Xiancheng" project was launched to connect new and established businesses, providing customized services to facilitate collaboration [5] - Fengxian plans to deepen industrial collaboration, focusing on innovation in AI and biomedicine, and support the establishment of R&D centers in partnership with universities and research institutions [5]

Core Insights - The 19th meeting of the Singapore-Jiangsu Cooperation Council was held in Nanjing, highlighting significant achievements in trade, investment, innovation, and cultural exchanges over the past year [1] - Future cooperation will focus on digital economy, biomedicine, service industry openness, and cultural tourism to deepen collaboration [1] - A memorandum of understanding was signed, and discussions were held on cooperation in modern services, biomedicine, and platform carriers, resulting in the signing of several key projects [1] Group 1 - The meeting was chaired by Liu Xiaotao, the Governor of Jiangsu, and attended by Singapore's Minister of State for Finance and National Development, Indranee Rajah [1] - The council aims to leverage the cooperation platform to enhance bilateral relations and achieve mutual benefits [1] - Key officials from both sides, including vice-chairpersons and ambassadors, participated in the meeting, indicating strong diplomatic engagement [1]

国乒混团世界杯三连胜 王曼昱：将全力以赴 12月2日，2025浙江省第六届"国际创客"创业创新大赛颁奖仪式在浙江义乌举行，澳门青年、某创业孵化机构负责人余茵华和澳门自媒体协会理事长黎翰澄 等人带队来此参赛、领奖，分享感受。 2019年至今，浙江省"国际创客"创业创新大赛连续举办六届，累计吸引海内外近6000名选手、1500余个项目参赛。本届大赛设置内地、港澳台侨、国际三大 赛道，共征集259个创业创新项目，内容覆盖人工智能、跨境电商、乡村振兴、生物医药等多个领域，旨在进一步整合全球创新资源、完善创业孵化链条、 强化政策支持力度，让更多创新理念在浙江落地生根、开花结果。(董易鑫 制作 侯诗蕊） ...

Group 1 - The IPO market in mainland China and Hong Kong shows a positive growth trend, with A-shares and Hong Kong accounting for 16% and 33% of global IPO numbers and fundraising amounts, respectively [1] - The Hong Kong Stock Exchange achieved a fundraising amount of $36 billion, ranking first globally, while A-shares experienced moderate growth with a significant increase in average fundraising amount, rising over 50% to 1 billion yuan [1] - The characteristics of this year's IPOs include a focus on technology innovation, with the industrial, technology, and materials sectors leading in the number of IPOs, and the energy sector rising in fundraising scale [1] Group 2 - The average fundraising scale for large IPOs increased by 137% compared to last year, reaching the second-highest level in five years, with the industrial and retail consumption sectors being the main contributors [2] - The capital markets in mainland China and Hong Kong are entering a complementary development phase, with international capital flowing into Hong Kong and a shift in investor structure from being foreign-led to a dual-driven model [2] - New consumption and hard technology are identified as the dual engines driving IPO activities in Hong Kong, supported by policies like the "Special Line for Science and Technology Enterprises" [2] Group 3 - A-shares will continue to advance under the framework of "stabilizing rhythm, improving quality, and optimizing structure," with the Beijing Stock Exchange becoming a key player in IPO applications and guidance [3] - The Hong Kong IPO market is expected to maintain its momentum, but with a more stable growth pace and structural deepening, with "A+H" models and the return of Chinese concept stocks being significant sources of listings [3]

Core Viewpoint - The stock price of Koyuan Pharmaceutical has experienced a decline of 4.68% year-to-date, with significant drops over various trading periods, indicating potential challenges in the company's market performance [2]. Company Overview - Koyuan Pharmaceutical, established on December 27, 2004, is located in Shandong, Jinan, and was listed on April 4, 2023. The company specializes in the research, production, and sales of chemical raw materials, finished pharmaceuticals, and pharmaceutical intermediates [2]. - The revenue composition of Koyuan Pharmaceutical is as follows: 44.77% from chemical raw materials, 41.41% from chemical drug formulations, 12.47% from intermediates, and 1.35% from other sources [2]. Stock Performance - As of December 3, Koyuan Pharmaceutical's stock price was 28.32 CNY per share, with a market capitalization of 3.067 billion CNY. The stock has seen a trading volume of 25.76 million CNY and a turnover rate of 1.31% [1]. - The stock has declined by 4.61% over the last five trading days, 10.38% over the last 20 days, and 19.09% over the last 60 days [2]. Financial Performance - For the period from January to September 2025, Koyuan Pharmaceutical reported a revenue of 303 million CNY, a year-on-year decrease of 8.52%. The net profit attributable to shareholders was 31.47 million CNY, down 20.69% year-on-year [2]. - The company has distributed a total of 85.085 million CNY in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, Koyuan Pharmaceutical had 11,100 shareholders, a decrease of 11.26% from the previous period. The average number of circulating shares per shareholder increased by 12.69% to 6,211 shares [2]. - Notably, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A has exited the list of the top ten circulating shareholders [3].

Core Viewpoint - The article discusses how Beijing Zhongguancun Bank, as the first private bank focused on serving technological innovation, has effectively supported early-stage tech companies lacking collateral over the past eight years [3][4]. Group 1: Strategic Positioning - Beijing Zhongguancun Bank has upgraded its strategic positioning from being a "provider of financial services" to a "builder of a technology financial ecosystem and a companion for innovative enterprises throughout their lifecycle" [3][4]. - The bank aims to contribute a "Zhongguancun sample" to the construction of the technology financial system [3][4]. Group 2: Key Focus Areas - The bank's service focus is summarized in eight characters: "grasp early, grasp small, grasp hard technology" [4]. - "Grasp early" refers to the ability to support emerging and future industries by providing financial assistance at the early stages of enterprise development [4]. - "Grasp small" indicates a focus on small and micro tech enterprises in their initial and growth stages, offering flexible and customized financial solutions [4]. - "Grasp hard technology" emphasizes investment in fields such as artificial intelligence, biomedicine, integrated circuits, new energy, new materials, and aerospace [4]. Group 3: Innovative Mechanisms - The bank has established a working mechanism that allows it to understand technology and entrepreneurship, ensuring effective matching of funds with projects [6]. - The bank has developed innovative financial products tailored to the unique needs of emerging industries, such as "Talent Benefit Plans," "Equity Rights Loans," and "Technology R&D Loans" [6]. - A case study illustrates how the bank provided crucial funding to a drone company during its early R&D phase, leading to significant growth and a valuation increase of 135% [7]. Group 4: Ecosystem Development - Beijing Zhongguancun Bank is building a more open innovation ecosystem by collaborating with venture capital institutions, industrial parks, incubators, accelerators, government funds, and research institutes [8]. - The bank has established partnerships with over 400 venture capital and industrial partners, facilitating shared customer resources, risk assessments, and project promotions [8]. - The bank is focusing on strategic emerging industries and aims to expand its ecosystem to promote collaborative development of technology finance across regions [8].